Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -15.67
- Piotroski Score 3.00
- Grade Buy
- Symbol (GOVX)
- Company GeoVax Labs, Inc.
- Price $2.70
- Changes Percentage (3.45%)
- Change $0.09
- Day Low $2.59
- Day High $2.74
- Year High $11.18
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/06/2025
- Fiscal Year End N/A
- Average Stock Price Target $8.00
- High Stock Price Target $8.00
- Low Stock Price Target $8.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$14.46
- Trailing P/E Ratio -0.11
- Forward P/E Ratio -0.11
- P/E Growth -0.11
- Net Income $-25,966,762
Income Statement
Quarterly
Annual
Latest News of GOVX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Geovax Labs Inc (GOVX) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges
The earnings call discussed steps for FDA approval of the A GE one cell line, timeline for trial results, and regulatory progress for the OX vaccine. FDA approval process for A GE one cell line is est...
By Yahoo! Finance | 1 week ago -
GOVX Stock Price | GeoVax Labs Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch
GeoVax Labs, Inc. is a biotech company developing vaccines and immunotherapies for infectious diseases and cancers. Founded in 1988, it focuses on preventing diseases like Ebola and Zika, as well as d...
By MarketWatch | 5 months ago
